Anti cyclin d1 antibody

Immunofluorescence and immunoblotting were performed as previously described [19 (link)]. The following antibodies were used for immunoblotting. Anti-KMT2D antibody (dilution 1:1000, #ABE1867, Sigma); anti-CD133 antibody (dilution 1:1000, #18,470, Proteintech); anti-ALDH1A1 antibody (dilution 1:2000, #15,910, Proteintech); anti-OCT4 antibody (dilution 1:1000, #11,263, Proteintech); anti-β-catenin antibody (dilution 1:2000, #51,067, Proteintech); anti-c-Myc antibody (dilution 1:100, #ab32072, Abcam); anti-Cyclin D1 antibody (dilution 1:1000, #26,939, Proteintech); anti-H3K4me1 antibody (dilution 1:500, #ab8895, Abcam); and anti-H3K27ac antibody (dilution 1:500, #ab4729, Abcam); anti-MEF2A antibody (dilution 1:500, #12,382, Proteintech). The following antibodies were used for immunofluorescence. Anti-KMT2D: antibody (dilution 1:100, #27,266, Proteintech); anti-CD133 antibody (dilution 1:200, #18,470, Proteintech); anti-β-catenin antibody (dilution 1:200, #51,067, Proteintech).

Rhein was purchased from MUST Biotech (Chengdu, China). LiCl was purchased from Sigma‐Aldrich (St. Louis, MO, USA). MG132 was from Merk Millipore Corporation (Darmstadt, Germany). Cycloheximide (CHX) was from Beyotime Biotechnology (Jiangsu, China). Anti‐β‐catenin, anti‐c‐Myc, anti‐PCNA, anti‐phosphorylated GSK‐3β (Ser9) antibodies were from Epitomics (Burlingame, CA, USA). Anti‐GSK3 antibody was from Signal way Antibody LLC (College Park, MD, USA). Anti‐cyclin‐D1 antibody was from Proteintech (Rosemont, IL, USA). The plasmid for phosphorylation‐deficient mutant of β‐catenin (S33A, S37A, T41A, S45A) was from Addgene (Cambridge, MA, USA).